Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (361-370 of 408) with videos related to

Pageof 41
Sort By:
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Cardiometabolic health in people with HIV: expert consensus reviewRachel L Batterham, Roger J Bedimo, Ricardo S Diaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting TreatmentsEthel D Weld, Jacqueline Astemborski, Gregory D Kirk, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirinS C Gordon, E M Yoshida, E J Lawitz, et al.
Gastroenterology|August 28, 2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseNorah A Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, et al.
JAMA|July 20, 2014
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfectionMark S Sulkowski, Susanna Naggie, Jacob Lalezari, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Pageof 41

Showing results (361-370 of 408) with videos related to

Sort By:
Pageof 41
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Cardiometabolic health in people with HIV: expert consensus reviewRachel L Batterham, Roger J Bedimo, Ricardo S Diaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting TreatmentsEthel D Weld, Jacqueline Astemborski, Gregory D Kirk, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirinS C Gordon, E M Yoshida, E J Lawitz, et al.
Gastroenterology|August 28, 2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseNorah A Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, et al.
JAMA|July 20, 2014
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfectionMark S Sulkowski, Susanna Naggie, Jacob Lalezari, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Pageof 41